Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: Study of 6-substituted pyridine-3-boronic acid derivatives

European Journal of Medicinal Chemistry

Volumn 95, Issue , 2015, Pages 185-198

  Fontaine, Fanny ^a,b   Héquet, Arnaud ^c   Voisin Chiret, Anne Sophie ^a,b   Bouillon, Alexandre ^e   Lesnard, Aurélien ^a,b   Cresteil, Thierry ^f   Jolivalt, Claude ^c,d   Rault, Sylvain ^a,b  

^a NORMANDIE UNIVERSITÉ   (France)

^b CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e BoroChem SAS   (France)

^f CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 BENZYLAMINO 5 BROMOPYRIDINE; 6 (1,3 BENZODIOXOL 5 YLMETHOXY)PYRIDINE 3 BORONIC ACID; 6 (2 PHENYLETHOXY)PYRIDINE 3 BORONIC ACID; 6 (2,4 DICHLOROPHENOXY)PYRIDINE 3 BORONIC ACID; 6 (3 PHENYLPROPOXY)PYRIDINE 3 BORONIC ACID; 6 (3,4 DICHLOROBENZYLOXY)PYRIDINE 3 BORONIC ACID; 6 (3,4,5 TRIMETHOXYBENZYLOXY)PYRIDINE 3 BORONIC ACID; 6 (4 CHLOROBENZYLOXY)PYRIDINE 3 BORONIC ACID; 6 (4 FLUOROBENZYLOXY)PYRIDINE 3 BORONIC ACID; 6 (4 PHENYLBUTOXY)PYRIDINE 3 BORONIC ACID; 6 (5 PHENYLPENTOXY)PYRIDINE 3 BORONIC ACID; 6 (6 PHENYLHEXYLOXY)PYRIDINE 3 BORONIC ACID; 6 BENZYLOXYPYRIDINE 3 BORONIC ACID; 6 BENZYLSULFANYLPYRIDINE 3 BORONIC ACID; 6 BUTOXYPYRIDINE 3 BORONIC ACID; 6 DODECANYLOXYPYRIDINE 3 BORONIC ACID; 6 HEPTYLOXYPYRIDINE 3 BORONIC ACID; 6 HEXYLOXYPYRIDINE 3 BORONIC ACID; 6 PENTOXYPYRIDINE 3 BORONIC ACID; 6 PHENOXYPYRIDINE 3 BORONIC ACID; 6 PROPOXYPYRIDINE 3 BORONIC ACID; ANTIBIOTIC AGENT; BORONIC ACID DERIVATIVE; CIPROFLOXACIN; DOCETAXEL; ETHIDIUM BROMIDE; GLYCOPROTEIN P INHIBITOR; NORA EFFLUX PUMP INHIBITOR; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; 6-(3-PHENYLPROPOXY)PYRIDINE-3-BORONIC ACID; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NORA PROTEIN, STAPHYLOCOCCUS;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG POTENTIATION; DRUG SCREENING; DRUG SYNTHESIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MINIMUM MODULATORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; KB CELL LINE; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BORONIC ACIDS; CIPROFLOXACIN; HUMANS; KB CELLS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PYRIDINES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84925688390     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.02.056     Document Type: Article

References (67)

1. S.B. Levy, B. Marshall, Antibacterial resistance worldwide: causes, challenges and responses, Nat. Med. 10 (2004) S122-S129.
2. M.N. Alekshun, S.B. Levy, Molecular mechanisms of antibacterial multidrug resistance, Cell 128 (2007) 1037-1050.
3. X.Z. Li, H. Nikaido, Efflux-mediated drug resistance in bacteria: an update, Drugs 69 (2009) 1555-1623.
4. H. Nikaido, Multidrug resistance in bacteria, Annu. Rev. Biochem. 78 (2009) 119-146.
5. P. Nordmann, T. Naas, N. Fortineau, L. Poirel, Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, enterococcus spp. and Pseudomonas aeruginosa in 2010, Curr. Opin. Microbiol. 10 (2007) 436-440.
6. D. Jabes, The antibiotic R&D pipeline: an update, Curr. Opin. Microbiol. 14 (2011) 564-569.
7. O. Lomovskaya, K.A. Bostian, Practical applications and feasibility of efflux pump inhibitors in the clinic e a vision for applied use, Biochem. Pharmacol. 71 (2006) 910-918.
8. J. Sun, Z. Deng, A. Yan, Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations, Biochem. Biophys. Res. Com. 453 (2014) 254-267.
9. A.S. Lynch, Efflux systems in bacterial pathogens: an opportunity for therapeutic intervention ? An industry view, Biochem. Pharmacol. 71 (2006) 949-956.
10. G. Ippolito, S. Leone, F.N. Lauria, E. Nicastri, R.P. Wenzel, Methicillin-resistant Staphylococcus aureus: the superbug, Int. J. Infect. Dis. 14S4 (2010) S7-S11.
11. C. Kosmidis, B.D. Schindler, P.L. Jacinto, D. Patel, K. Bains, S.M. Seo, G.W. Kaatz, Expression of multidrug resistance efflux pump genes in clinical and environmental isolates of Staphylococcus aureus, Int. J. Antimicrob. Agents 40 (2012) 204-209.
12. H. Yoshida, M. Bogaki, S. Nakamura, K. Ubukata, M. Konno, Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones, J. Bacteriol. 172 (1990) 6942-6949.
13. A.A. Neyfakh, C.M. Borsch, G.W. Kaatz, Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter, Antimicrob. Agents Chemother. 37 (1993) 128-129.
14. J. Handzlik, A. Matys, K. Kiec-Kononowicz, Recent advances in multi-drug resistance (MDR) efflux pump inhibitors of gram-positive bacteria S. aureus, Antibiotics 2 (2013) 28-45.
15. F.J. Schmitz, A.C. Fluit, M. Lückefahr, B. Engler, B. Hofmann, J. Verhoef, H.P. Heinz, U. Hadding, M.E. Jones, The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus, J. Antimicrob. Chemother. 42 (1998) 807-810.
16. M. Stavri, L.J.V. Piddock, S. Gibbons, Bacterial efflux pump inhibitors from natural sources, J. Antimicrob. Chemother. 59 (2007) 1247-1260.
17. N.R. Guz, F.R. Stermitz, J.B. Johnson, T.D. Beeson, S. Willen, J.F. Hsiang, K. Lewis, Flavonolignan and flavones inhibitors of Staphylococcus aureus multidrug resistance pump: structure-activity relationships, J. Med. Chem. 44 (2001) 261-268.
18. B.C. Chan, M. Ip, C.B. Lau, S.L. Lui, C. Jolivalt, C. Ganem-Elbaz, M. Litaudon, N.E. Reiner, H. Gong, R.H. See, K.P. Fung, P.C. Leung, Synergistic effects of baicalein with ciprofloxacin against NorA over-expressed methicillin-resistant Staphylococcus aureus (MRSA) and inhibition of MRSA pyruvate kinase, J. Ethnopharmacol. 137 (2011) 767-773.
19. S. Michalet, G. Cartier, B. David, A.M. Mariotte, M.G. Dijoux-Franca, G.W. Kaatz, M. Stavri, S. Gibbons, N-caffeoylphenalkylamide derivatives as bacterial efflux pump inhibitors, Bioorg. Med. Chem. Lett. 17 (2007) 1755-1758.
20. A. Kumar, I.A. Khan, S. Koul, J.L. Koul, S.C. Taneja, I. Ali, F. Ali, S. Sharma, Z.M. Mirza, M. Kumar, P.L. Sangwan, P. Gupta, N. Thota, G.N. Qazi, Novel structural analogues of piperine as inhibitors of the NorA efflux pump of Staphylococcus aureus, J. Antimicrob. Chemother. 61 (2008) 1270-1276.
21. N. Thota, S. Koul, M.V. Reddy, P.L. Sangwan, I.A. Khan, A. Kumar, A.F. Raja, S.S. Andotra, G.N. Qazi, Citral derived amides as potent bacterial NorA efflux pump inhibitors, Bioorg. Med. Chem. 16 (2008) 6535-6543.
22. R. Pereda-Miranda, G.W. Kaatz, S. Gibbons, Polyacylated oligosaccharides from medicinal Mexican morning glory species as antibacterials and inhibitors of multidrug resistance in Staphylococcus aureus, J. Nat. Prod. 69 (2006) 406-409.
23. S. Samosorn, J.B. Bremner, A. Ball, K. Lewis, Synthesis of functionalized 2-aryl- 5-nitro-1H-indoles and their activity as bacterial NorA efflux pump inhibitors, Bioorg. Med. Chem. 14 (2006) 857-865.
24. A. Hequet, O.N. Burchak, M. Jeanty, X. Guinchard, E. Le Pihive, L. Maigre, P. Bouhours, D. Schneider, M. Maurin, J.M. Paris, J.N. Denis, C. Jolivalt, 1-(1Hindol- 3-yl)ethanamine derivatives as potent Staphylococcus aureus NorA efflux pump inhibitors, ChemMedChem. 9 (2014) 1534-1545.
25. N. German, G.W. Kaatz, R.J. Kerns, Synthesis and evaluation of PSSRI-based inhibitors of Staphylococcus aureus multidrug efflux pumps, Bioorg. Med. Chem. Lett. 18 (2008) 1368-1373.
26. J. Fournier dit Chabert, B. Marquez, L. Neville, L. Joucla, S. Broussous, P. Bouhours, E. David, S. Pellet-Rostaing, B. Marquet, N. Moreau, M. Lemaire, Synthesis and evaluation of new arylbenzo[b]thiophene and diarylthiophene derivatives as inhibitors of the NorA multidrug transporter of Staphylococcus aureus, Bioorg. Med. Chem. 15 (2007) 4482-4497.
27. G.W. Kaatz, V.V. Moudgal, S.M. Seo, J.E. Kristiansen, Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus, Antimicrob. Agents Chemother. 47 (2003) 719-726.
28. S. Sabatini, G.W. Kaatz, G.M. Rossolini, D. Brandini, A. Fravolini, From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump, J. Med. Chem. 51 (2008) 4321-4330.
29. S. Sabatini, F. Gosetto, G. Manfroni, O. Tabarrini, G.W. Kaatz, D. Patel, V. Cecchetti, Evolution from a natural flavones nucleus to obtain 2-(4- propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump, J. Med. Chem. 54 (2011) 5722-5736.
30. M. Pieroni, M. Dimovska, J.P. Brincat, S. Sabatini, E. Carosati, S. Massari, G.W. Kaatz, A. Fravolini, From 6-aminoquinolone antibacterials to 6-amino-7- thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps, J. Med. Chem. 53 (2010) 4466-4480.
31. S. Sabatini, F. Gosetto, S. Serritella, G. Manfroni, O. Tabarrini, N. Iraci, J.P. Brincat, E. Carosati, M. Villarini, G.W. Kaatz, V. Cecchetti, Pyrazolo[4,3-c] [1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors, J. Med. Chem. 55 (2012) 3568-3572.
32. N. Miyaura, A. Suzuki, Palladium-catalyzed cross-coupling reactions of organoboron compounds, Chem. Rev. 95 (1995) 2457-2483.
33. D. Chen, M. Frezza, S. Schmitt, J. Kanwar, Q.P. Dou, Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives, Curr. Cancer Drug Targets 11 (2011) 239-253.
34. a) J.Q. Del Rosso, J.J. Plattner, From the test tube to the treatment room: fundamentals of boron-containing compounds and their relevance to dermatology, J. Clin. Aesthet. Dermatol 7 (2014) 13-21
35. Anacor Pharmaceuticals Announces Commercial Launch of KERYDIN (Tavaborole) Topical Solution, 5% in the United States, Sep 22, 2014. Press Release.
36. S.J. Baker, C.Z. Ding, T. Akama, Y.K. Zhang, V. Hernandez, Y. Xia, Therapeutic potential of boron-containing compounds, Future Med. Chem. 1 (2009) 1275-1288.
37. J.A. Settepani, J.B. Stokes, A.B. Borkovec, Insect chemosterilants. VIII. Boron compounds, J. Med. Chem. 13 (1970) 128-131.
38. S.J. Baker, Y.K. Zhang, T. Akama, A. Lau, H. Zhou, V. Hernandez, W. Mao, M.R.K. Alley, V. Sanders, J.J. Plattner, Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), for the potential treatment of onychomycosis, J. Med. Chem. 49 (2006) 4447-4450.
39. Y.K. Zhang, J.J. Plattner, Y.R. Freund, E.E. Easom, Y. Zhou, J. Gut, P.J. Rosenthal, D. Waterson, F.J. Gamo, I. Angulo-Barturen, M. Ge, Z. Li, L. Li, Y. Jian, H. Chui, H. Wang, J. Yang, Synthesis and structure-activity relationship of novel benzoxaboroles as a new class of antimalarial agents, Bioorg. Med. Chem. Lett. 21 (2011) 644-651.
40. X. Li, Y.K. Zhang, Y. Liu, C.Z. Ding, Q. Li, Y. Zhou, J.J. Plattner, S.J. Baker, X. Qian, D. Fan, L. Liao, Z.J. Ni, G.V. White, J.E. Mordaunt, L.X. Lazarides, M.J. Slater, R.L. Jarvest, P. Thommes, M. Ellis, C.M. Edge, J.A. Hubbard, D. Somers, P. Rowland, P. Nassau, B. McDowell, T.J. Skarzynski, W.M. Kazmierski, R.M. Grimes, L.L. Wright, G.K. Smith, W. Zou, J. Wright, L.E. Pennicott, Synthesis and evaluation of novel a-amino cyclic boronates as inhibitors of HCV NS3 protease, Bioorg. Med. Chem. Lett. 20 (2010) 3550-3556.
41. T. Akama, S.J. Baker, Y.K. Zhang, V. Hernandez, H. Zhou, V. Sanders, Y. Freund, R. Kimura, K.R. Maples, J.J. Plattner, Discovery and structure-activity relationship study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriaris and atopic dermatitis, Bioorg. Med. Chem. Lett. 19 (2009) 2129-2132.
42. R. Smoum, A. Rubinstein, V.M. Dembitsky, M. Srebnik, Boron containing compounds as protease inhibitors, Chem. Rev. 112 (2012) 4156-4220.
43. M.A. Grassberger, F. Turnowsky, J. Hildebrandt, Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogues, J. Med. Chem. 27 (1984) 947-953.
44. V. Hernandez, T. Crepin, A. Palencia, S. Cusack, T. Akama, S.J. Baker, W. Bu, L. Feng, Y.R. Freund, L. Liu, M. Meewan, M. Mohan, W. Mao, F.L. Rock, H. Sexton, A. Sheoran, Y. Zhang, Y.K. Zhang, Y. Zhou, J.A. Nieman, M.R. Anugula, E.M. Keramane, K. Savariraj, D.S. Reddy, R. Sharma, R. Subedi, R. Singh, A. O'Leary, N.L. Simon, P.L. De Marsh, S. Mushtaq, M. Warner, D.M. Livermore, M.R.K. Alley, J.J. Plattner, Discovery of a novel class of boronbased antibacterials with activity against gram-negative bacteria, Antimicrob. Agents Chemother. 57 (2013) 1394-1403.
45. Y. Xia, K. Cao, Y. Zhou, M.R.K. Alley, F. Rock, M. Mohan, M. Meewan, S.J. Baker, S. Lux, C.Z. Ding, G. Jia, M. Kully, J.J. Plattner, Synthesis and SAR of novel benzoxaboroles as a new class of b-lactamase inhibitors, Bioorg. Med. Chem. Lett. 21 (2011) 2533-2536.
46. A. Jabbour, D. Steinberg, V.M. Dembitsky, A. Moussaieff, B. Zaks, M. Srebnik, Synthesis and evaluation of oxazaborolidines for antibacterial activity against Streptococcus mutans. J, Med. Chem. 47 (2004) 2409-2410.
47. S.J. Benkovic, S.J. Baker, M.R.K. Alley, Y.H. Woo, Y.K. Zhang, T. Akama, W. Mao, J. Baboval, P.T. Ravi Rajagopalan, M. Wall, L.S. Kahng, A. Tavassoli, L. Shapiro, Identification of borinic esters as inhibitors of bacterial cell growth and bacterial methyltransferases CcrM and MenH, J. Med. Chem. 48 (2005) 7468-7476.
48. A.M. Irving, C.M. Vogels, L.G. Nikolcheva, J.P. Edwards, X.F. He, M.G. Hamilton, M.O. Baerlocher, F.J. Baerlocher, A. Decken, S.A. Westcott, Synthesis and antifungal and antibacterial bioactivity of cyclic diamines containing boronate esters, New. J. Chem. 27 (2003) 1419-1424.
49. F. Morandi, E. Caselli, S. Morandi, P.J. Focia, J. Blazquez, B.K. Shoichet, F. Prati, Nanomolar inhibitors of AmpC b-lactamase, J. Am. Chem. Soc. 125 (2003) 685-695.
50. D.M. Livermore, S. Mushtaq, Activity of biapenem (RPX2003) combined with the boronate b-lactamase inhibitor RPX7009 against carbapenem-resistant enterobacteriaceae, J. Antimicrob. Chemother. 68 (2013) 1825-1831.
51. F. Fontaine, A. Hequet, A.S. Voisin-Chiret, A. Bouillon, A. Lesnard, T. Cresteil, C. Jolivalt, S. Rault, First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump, J. Med. Chem. 57 (2014) 2536-2548.
52. A.A. Neyfakh, Mystery of multidrug transporters: the answer can be simple, Mol. Microbiol. 44 (2002) 1123-1130.
53. Pulman D.A., Ying B., Wu S., Gupta S., Shimoharada H., Tsukamoto M. Preparation of diaryl ethers as herbicides and desiccants. PCT Int. Appl. WO9841093.
54. D. Cai, R.D. Larsen, P.J. Reider, Effective lithiation of 3-bromopyridine: synthesis of 3-pyridine boronic acid and variously 3-substituted pyridines, Tetrahedron Lett. 43 (2002) 4285-4287.
55. http://www.chemaxon.com/products/marvin/marvinsketch.
56. T. Cailly, F. Fabis, S. Lemaitre, A. Bouillon, S. Rault, Synthesis of orthosubstituted cyanopyridines through lithio intermediate trapping, Tetrahedron Lett. 46 (2005) 135-137.
57. Wu G., Spevak W., Shi S., Cho H., Ibrahim P.N., Zhang C., Shi S., Zhou Y., Artis D.R., Zhang J. Pyrrolo[2,3-b]pyridines as kinase modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases. PCT Int. Appl. WO2008079909.
58. G.W. Kaatz, S.M. Seo, C.A. Ruble, Mechanisms of fluoroquinolone resistance in Staphylococcus aureus, J. Inf. Dis. 163 (1991) 1080-1086.
59. LogP values were calculated using the Marvin Sketch online software but they were not confirmed with experimental data (http://www.chemaxon.com/ products/marvin/marvinsketch).
60. S. Sabatini, F. Gosetto, S. Serritella, G. Manfroni, O. Tabarrini, N. Iraci, J.P. Brincat, E. Carosati, M. Villarini, G.W. Kaatz, V. Cecchetti, Pyrazolo[4,3-c] [1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors, J. Med. Chem. 55 (2012) 3568-3572.
61. J.P. Brincat, F. Broccatelli, S. Sabatini, M. Frosini, A. Neri, G.W. Kaatz, G. Cruciani, E. Carosati, Ligand promiscuity between the efflux pumps human P-glycoprotein and S. aureus NorA, ACS Med. Chem. Lett. 3 (2012) 248-251.
62. P. Joshi, S. Singh, A. Wani, S. Sharma, S.K. Jain, B. Singh, B.D. Gupta, N.K. Satti, S. Koul, I.A. Khan, A. Kumar, S.B. Bharate, R.A. Vishwakarma, Osthol and curcumin are inhibitors of human Pgp and multidrug efflux pumps of Staphylococcus aureus: reversing the resistance against frontline antibacterial drugs, Med. Chem. Comm. 5 (2014) 1540-1547.
63. Kim B.T., Min Y.K., Heo J.N., Lee H., Chang S.Y., Park N.K., Song S.W., Oh J.J. Triazole derivatives having antifungal activity, method for the preparation thereof, and pharmaceutical composition comprising the same. PCT Int. Appl. WO2008153325.
64. Tanaka K., Yamamoto E., Watanabe N. Pyridine derivative substituted with heterocycle and phosphonoamino and antifungal agent containing the same. PCT Int. Appl. WO2008136324.
65. Cheng H., Dress K.R., Huang B., Kupchinsky S.W., Le P.T., Smith C.R., Wang Y., Yang Y. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1. PCT Int. Appl. WO2006134481.
66. M. Monali, R. Aparna, R. Sumita, Effect of pH and oxygen atom of the hydrophobic chain on the self-assembly property and morphology of the pyridyl boronic acid based amphiphiles, Langmuir 29 (2013) 13329-13338.
67. A. Breteche, P. Marchand, M.R. Nourrisson, P. Hautefaye, G. De Nanteuil, M.A. Duflos, A convenient route to functionalized 3-amino-N-methylfuro[3,2- b]pyridine-2-carboxamides, Tetrahedron 67 (2011) 4767-4773.